2026年3月3日，泰格医药集团旗下方达控股宣布已正式完成对观合医药的收购。此次收购将进一步完善 方达在全球中心实验室领域的布局，强化其在中国及亚太地区的综合服务能力。 观合医药是中国领先的临床研究实验室服务提供商，累计支持超过1,500项临床试验，覆盖多个治疗领 域。公司长期按照GCP规范开展运营，实验室通过CAP认证，同时获得NGSP Level 1实验室资质，并具 备放射性乙类工作场所资质。凭借成熟稳健的运营体系，观合医药持续为国内外制药企业和生物技术公 司提供符合国际监管要求、可支持审计的高质量实验室检测服务。在支持监管核查及新药注册申报方 面，公司积累了丰富经验，已助力50个新药成功获批上市。 收购完成后，方达控股将在中国进一步拓展中心实验室网络布局，提升对国内临床研究及多区域临床试 验（MRCT）的综合支持能力。通过整合观合医药在中心实验室领域的成熟运营经验，以及方达覆盖生 物分析、DMPK、安全性评价、CMC和临床研究支持等在内的一体化服务平台，方达将进一步提升端 到端研发服务能力，为全球制药企业、生物技术公司及科研机构提供更加高效、合规、协同的综合解决 方案。 方达控股相关负责人表示： "观合 ...

证券日报网讯2月13日，百花医药（600721）在互动平台回答投资者提问时表示，2025年年审工作正在 进行中，2026年公司将不断强化在医药CRO及相关领域的竞争优势，积极优化业务布局，加强技术创 新，进一步加快客户拓展步伐，持续推进公司的高质量发展，具体情况请关注公司后续的定期报告。公 司指定的信息披露媒体为上海证券交易所网站及《上海证券报》《证券日报》，公司所有信息均以上述 指定媒体刊登的公告为准。请注意投资风险。 ...

Group 1 - The CRO index experienced a partial increase on January 30, with Tigermed leading the gains at 7.83% [1] - Other companies such as Nossan, Sunshine Nuohe, Boji Medical, and Baicheng Medical also saw increases, with respective gains of 5.88%, 1.41%, 0.85%, and 0.75% [1]

Market Overview - The A-share market opened higher on January 5, with the Shanghai Composite Index surpassing 4000 points, closing at 4023.42 points, up 1.38% [2] - The total trading volume in the Shanghai and Shenzhen markets reached 25,462 billion yuan, an increase of 5,011 billion yuan from the previous trading day [2] Sector Performance - The pharmaceutical and biotechnology sectors saw significant gains, with nearly 40 stocks hitting the daily limit or rising over 10%, driven by industry demand recovery and exceeding performance expectations [4] - Non-bank financial stocks, particularly insurance companies, performed well, with several stocks rising over 5% to 7% due to stable growth in investment assets and high dividend strategies [5] - The semiconductor sector also showed strong performance, with multiple stocks rising over 10% [6] Market Sentiment and Predictions - Analysts from Huaxi Securities believe the bull market remains intact, with 2026 expected to be a year of positive factors, including supportive macro policies and improved corporate earnings [8] - Zhongyuan Securities anticipates that the market will stabilize around the 4000-point mark, with a focus on macroeconomic data and overseas liquidity changes [9] - Citic Securities suggests that the balance between external and internal demand will be a significant factor in 2026, with a higher probability of market fluctuations in the early year [10]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights that various segments within the pharmaceutical industry have seen multiple stocks with over 100% gains in 2025, particularly in the chemical preparation sector, which has outperformed due to the rise in valuations of innovative drugs and strong clinical data from pipelines [4][13] - The report anticipates continued opportunities in the innovative drug sector, driven by the global competitiveness of Chinese pharmaceutical companies and the recognition of their R&D capabilities by multinational corporations [5][14] - Emerging industries such as AI, brain-computer interfaces, and biomanufacturing are expected to gradually transform various segments of the pharmaceutical field, with ongoing efforts to identify investment opportunities within these areas [5][14] Summary by Sections 1. Performance of Pharmaceutical Segments - In 2025, the chemical preparation sector showed the best performance, with top stocks like Shuyou Shen, Guangsheng Tang, and Anglikang achieving over 100% gains due to favorable clinical data and valuation increases [4][13] - The bioproducts sector, including companies like Sanofi and Rongchang Biopharma, also saw significant gains driven by quality pipelines and business development opportunities abroad [4][13] - The pharmaceutical R&D outsourcing sector experienced a "Davis Double" effect, with companies like WuXi AppTec and Haoyuan Pharmaceutical reporting exceptional performance due to increased demand and exceeding expectations [4][13] 2. Market Trends and Weekly Performance - In the fifth week of December 2025, the pharmaceutical sector declined by 2.06%, underperforming the CSI 300 index by 1.47 percentage points, ranking 28th among 31 sub-industries [6][18] - The hospital sector had the smallest decline at 0.85%, while the offline pharmacy sector faced the largest drop at 4.11% [6][22] 3. Recommendations and Focus Areas - The report continues to recommend investment in the innovative drug sector and its supply chain, particularly in CXO and R&D services, as well as in emerging industries like AI and biomanufacturing [5][7][14] - Monthly and weekly stock recommendations include WuXi AppTec, Sanofi, and Haoyuan Pharmaceutical, among others, indicating a focus on companies with strong growth potential [7][15]

Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) emphasizes its focus on new drug research and development services as a CRO, highlighting a significant difference in business model compared to internet companies that provide C-end healthcare services [1] Group 1 - The company has not engaged in C-end health medical project collaborations with Alibaba or other internet platforms [1]

Group 1 - The stock of Zhaoyan New Drug (06127) has fallen over 5%, but it has still seen a cumulative increase of more than 24% in the month [1] - As of the report, the stock price is at 20.5 HKD with a trading volume of 151 million HKD [1] - The price of experimental monkeys is on an upward trend, reaching approximately 140,000 RMB each as of December 9, 2025 [1] Group 2 - According to Founder Securities, the demand for experimental monkeys is increasing due to a steady recovery in preclinical CRO orders, while supply-side expansion is challenging in the short term [1] - Some monkey farms have reported that their production capacity is already booked until the first quarter of 2026, indicating a tight supply-demand situation that is expected to persist [1] - For Zhaoyan New Drug, assuming an average price of 84,900 RMB per monkey in 2024 and an increase to 140,000 RMB by Q4 2025, the estimated new fair value in 2025 could be around 220 million RMB based on known quantities [1]

Core Viewpoint - The strong market performance of Zhaoyan New Drug, which reached a limit-up price of 30.77 yuan per share, is influenced by the announcement of the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security regarding the new drug catalog effective from January 1, 2026 [1] Group 1: Company Overview - Zhaoyan New Drug is one of the earliest private CRO companies in China engaged in non-clinical drug evaluation, providing a range of services including non-clinical pharmacology and toxicology research, clinical trials, and drug safety monitoring [1] - The company also offers evaluation services for veterinary drugs, pesticides, and medical devices [1] Group 2: Recent Announcements - On December 6, Zhaoyan New Drug announced that it expects to provide pharmaceutical R&D outsourcing services to its affiliate, Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd., and its subsidiaries, with a transaction amount not exceeding 47 million yuan, which is expected to account for no more than 10% of similar business [1] - Historical data indicates that the actual transaction amount with Shuyou Shen in 2024 was 21.97 million yuan, and from the beginning of 2025 to October 31, the cumulative amount was 12.2 million yuan [1] - The company stated that the transactions are necessary for daily operations, are priced fairly, and will not affect its independence [1]

Summary of Key Points from the Conference Call on Small Nucleic Acid CDMO Industry Overview - The discussion focuses on the small nucleic acid industry, particularly the Contract Development and Manufacturing Organization (CDMO) sector, which is experiencing growth and transformation due to technological advancements and market dynamics [1][10]. Core Insights and Arguments - **Cost Structure of Small Nucleic Acids**: The raw material cost for small nucleic acid APIs constitutes about 10% of the total drug cost, with total production costs around 20% when including formulation costs. Future advancements in technology and economies of scale are expected to further reduce these costs over the next three to five years [1][3]. - **Raw Material Price Trends**: The prices of key raw materials have significantly decreased, with monomer prices dropping to 1/10 to 1/15 of their previous levels five years ago. The industry has seen a shift from reliance on imported carriers to domestic production [3][4]. - **Impact of Technology on Costs**: Enzymatic synthesis is noted to save 10%-20% in production costs compared to solid-phase synthesis due to higher yields and simpler purification processes. Continuous optimization of these technologies is anticipated to further lower overall costs [6][10]. - **Pricing Discrepancies Among CDMO Firms**: There is a notable price difference between leading CDMO firms like WuXi AppTec and new entrants, with the latter often engaging in low-price competition to gain experience. For instance, quotes for clinical phase I RGP submissions can vary from 6 million to 15 million yuan depending on the company [8][9]. - **Market Capacity and Risks**: The small nucleic acid market faces potential overcapacity risks, primarily due to limited therapeutic targets outside of liver-targeted applications. New entrants may struggle to find demand in the next three years [10][12]. - **Order Stickiness and Market Concentration**: The collaboration between small nucleic acid companies and CDMO firms is characterized by high order stickiness, making it difficult for clients to switch suppliers. Leading firms are expected to maintain a high market concentration due to their experience and process development capabilities [10][11]. Additional Important Insights - **Geopolitical Influences**: The tension in US-China relations may lead to shifts in order allocations, as seen with Novartis moving orders to South Korean firms. Improved relations could allow Chinese companies to regain opportunities, contingent on diplomatic developments [2][14]. - **Future Market Potential**: Several small nucleic acid products in development, such as GSK836 for hepatitis B, are projected to have significant market potential, with expected launches in the coming years [14]. - **Technological Advancements in Delivery Systems**: Innovations in delivery systems are likely to influence production processes within the small nucleic acid CDMO sector, although the core synthesis methods remain largely unchanged [22]. - **Competitive Landscape**: The competitive landscape is evolving, with established players like Alnylam relying on external CDMO partnerships for large-scale production while maintaining some in-house capabilities for process development [18]. - **Regulatory Compliance**: Compliance with regulations is a primary consideration for multinational corporations when selecting CDMO partners, emphasizing the importance of adhering to industry standards [7]. This summary encapsulates the critical aspects of the small nucleic acid CDMO industry as discussed in the conference call, highlighting the interplay of cost structures, technological advancements, market dynamics, and geopolitical factors.

Group 1 - Medisi announced that shareholder Lin Changqing holds approximately 4.11 million shares, accounting for 3.06% of the total share capital [1] - After the release of the pledge, Lin Changqing has pledged a total of 2.4 million shares, which is 58.34% of his total holdings and 1.79% of the company's total share capital [1] - For the year 2024, Medisi's revenue composition is projected to be 99.96% from preclinical CRO business and 0.04% from other businesses [1] Group 2 - As of the report, Medisi's market capitalization is 9.3 billion yuan [1]